You are here

UCB to sell its US specialty generics business Kremers Urban to Lannett for $1.23 billion

  • US$ 1.23 billion upfront payment plus potential contingent payments related to methylphenidate HCI ER
  • Enhanced focus on UCB's core business in CNS and immunology
  • Proceeds will be used for reduction of debt, increasing strategic flexibility

Brussels (Belgium), 2 September 2015 – 10:30pm (CEST) – regulated information – UCB and Lannett Company, Inc. (NYSE: LCI) today announced they have entered into a definitive agreement providing for the acquisition of UCB’s U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc. ("KU"), by Lannett. UCB will receive upfront cash proceeds of US$ 1.23 billion upon closing, which is subject to regulatory approval and other customary closing conditions. In addition, UCB is eligible to receive contingent payments for methylphenidate HCI ER in the event that the product’s AB-rating is restored, allowing UCB to participate in potential upside in the product.

UCB plans to use the proceeds from this divestiture to reduce indebtedness and increase the company's capacity for strategic investments, to further accelerate growth and/or to further strengthen its innovative medicines pipeline.

"Kremers Urban has been an important enabler building UCB's core business. We thank our Kremers Urban colleagues for their excellent performance and their focus and persistency throughout this selling process," said Detlef Thielgen, CFO of UCB. "UCB's focus is now entirely on our core business while offering Kremers Urban further growth opportunities together with Lannett."

The purchase price is payable to UCB in cash upon closing. This transaction announced today has been unanimously approved by both UCB's and Lannett’s Boards of Directors and is expected to close in the fourth quarter of 2015, subject to the satisfaction of customary closing conditions.

The UCB 2015 financial outlook remains unchanged.

Lazard is acting as lead financial advisor to UCB, BNP Paribas is acting as additional financial advisor and Covington & Burling LLP is acting as legal counsel to UCB.